Tumor mutational burden (TMB) and response rates to immune checkpoint inhibitors (ICIs) targeting PD-1, CTLA-4, and combination.

被引：5
|
作者：
Osipov, Arsen
Popovic, Aleksandra
Hopkins, Alexander
Frampton, Garrett M.
Albacker, Lee A.
Azad, Nilofer Saba
Laheru, Daniel A.
Zheng, Lei
Jaffee, Elizabeth M.
Yarchoan, Mark
机构：
[1] Johns Hopkins Univ, Sch Med, Dept Oncol, Balimore, MD USA
[2] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[3] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] Fdn Med Inc, Cambridge, MA USA
[5] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[6] Johns Hopkins Univ Hosp, Baltimore, MD USA
[7] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.2578
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2578
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Tumor Mutational Burden, Toxicity, and Response of Immune Checkpoint Inhibitors Targeting PD(L)1, CTLA-4, and Combination: A Meta-regression Analysis
    Osipov, Arsen
    Lim, Su Jin
    Popovic, Aleksandra
    Azad, Nilofer S.
    Laheru, Daniel A.
    Zheng, Lei
    Jaffee, Elizabeth M.
    Wang, Hao
    Yarchoan, Mark
    CLINICAL CANCER RESEARCH, 2020, 26 (18) : 4842 - 4851
  • [2] Panel-derived tumor mutational burden (TMB) correlates with immune checkpoint inhibitors (ICIs) response in gastrointestinal cancers
    Chen, San-chi
    Tan, Kien-Thiam
    Chen, Ming-Huang
    Hung, Yi-Ping
    Hsieh, Yi-Lin
    Jan, Yi-Hua
    Chao, Yee
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [3] Panel-derived tumor mutational burden (TMB) is associated with the response to the immune checkpoint inhibitors (ICIs) in urothelial cancers
    Hsieh, Yi-Lin
    Yu, Pei-Ning
    Jan, Yi-Hua
    Lai, Meng-Shao
    Wang, Woei-Fuh
    Zhuo, De-Wei
    Chen, Shu-Jen
    Cheng, Jen-Hao
    Tan, Kien Thiam
    Su, Yu-Li
    CANCER RESEARCH, 2020, 80 (16)
  • [4] Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune Silencing
    Goepfert, Katrin
    Dinsart, Christiane
    Rommelaere, Jean
    Foerster, Friedrich
    Moehler, Markus
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [5] Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)
    Wu, Yingcheng
    Ju, Qianqian
    Jia, Keren
    Yu, Jingyan
    Shi, Hui
    Wu, Huiqun
    Jiang, Maorong
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (01) : 45 - 51
  • [6] Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
    Qin, Shuang
    Xu, Linping
    Yi, Ming
    Yu, Shengnan
    Wu, Kongming
    Luo, Suxia
    MOLECULAR CANCER, 2019, 18 (01)
  • [7] The future of immune checkpoint cancer therapy after PD-1 and CTLA-4
    Hahn, Andrew W.
    Gill, David M.
    Pal, Sumanta K.
    Agarwal, Neeraj
    IMMUNOTHERAPY, 2017, 9 (08) : 681 - 692
  • [8] Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
    Shuang Qin
    Linping Xu
    Ming Yi
    Shengnan Yu
    Kongming Wu
    Suxia Luo
    Molecular Cancer, 18
  • [9] Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).
    Labriola, Matthew
    Zhu, Jason
    Gupta, Rajan
    McCall, Shannon
    Jackson, Jennifer
    White, James R.
    Weingartner, Elizabeth
    Kong, Eric
    Simone, Peter
    Papp, Eniko
    Gerding, Kelly
    Simmons, John
    George, Daniel J.
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [10] Immune checkpoint therapy: From CTLA-4 to PD-1/PD-L1 and beyond
    Sharma, Padmanee
    CANCER RESEARCH, 2018, 78 (13)
12345